Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

VXRT – Vaxart, Inc.

Vaxart, Inc. - Common Stock
VXRT
$0.4053
Name : Vaxart, Inc. - Common Stock
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $92,498,784.00
EPSttm : -0.26
finviz dynamic chart for VXRT
Vaxart, Inc. - Common Stock
$0.4053
2.48%
$0.0098

Float Short %

6.46

Margin Of Safety %

Put/Call OI Ratio

0.05

EPS Next Q Diff

0.01

EPS Last/This Y

0.04

EPS This/Next Y

-0.05

Price

0.4

Target Price

4.67

Analyst Recom

1

Performance Q

-13.73

Relative Volume

0.43

Beta

1.15

Ticker: VXRT




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-08VXRT0.40310.060.129084
2025-05-09VXRT0.41980.060.119089
2025-05-12VXRT0.40620.060.009176
2025-05-13VXRT0.41050.060.009212
2025-05-14VXRT0.40870.060.009811
2025-05-15VXRT0.4210.050.0410187
2025-05-16VXRT0.50990.050.0110270
2025-05-19VXRT0.49380.050.039837
2025-05-20VXRT0.50730.050.039983
2025-05-21VXRT0.45750.050.0110145
2025-05-22VXRT0.4660.050.1110249
2025-05-23VXRT0.46340.060.0510290
2025-05-27VXRT0.460.060.0410350
2025-05-28VXRT0.450.060.0210421
2025-05-29VXRT0.46230.060.0510526
2025-05-30VXRT0.43310.060.0210670
2025-06-02VXRT0.4480.050.0010975
2025-06-03VXRT0.41610.050.8211023
2025-06-04VXRT0.40140.050.0511001
2025-06-05VXRT0.39440.050.1911303
2025-06-06VXRT0.4050.050.2511426
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-08VXRT0.4050.0- -0.34
2025-05-09VXRT0.4250.0- -0.34
2025-05-12VXRT0.4150.0- -0.34
2025-05-13VXRT0.4250.0- -0.34
2025-05-14VXRT0.4150.0- -0.34
2025-05-15VXRT0.4250.0- -0.34
2025-05-16VXRT0.5150.0- -0.34
2025-05-19VXRT0.50-22.2- -0.34
2025-05-20VXRT0.51-22.2- -0.34
2025-05-21VXRT0.46-22.2- -0.34
2025-05-22VXRT0.46-22.2- -0.34
2025-05-23VXRT0.46-22.2- -0.34
2025-05-27VXRT0.46-22.2- -0.34
2025-05-28VXRT0.45-22.2- -0.34
2025-05-29VXRT0.46-22.2- -0.34
2025-05-30VXRT0.43-22.2- -0.34
2025-06-02VXRT0.45-22.2- -0.29
2025-06-03VXRT0.42-5.6- -0.29
2025-06-04VXRT0.40-5.6- -0.29
2025-06-05VXRT0.40-5.6- -0.29
2025-06-06VXRT0.40-5.6- -0.29
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-08VXRT0.00-16.095.91
2025-05-09VXRT0.00-16.095.91
2025-05-12VXRT0.00-17.155.41
2025-05-13VXRT0.00-17.155.41
2025-05-14VXRT0.00-17.155.41
2025-05-15VXRT0.00-17.155.41
2025-05-16VXRT0.00-17.155.41
2025-05-19VXRT0.00-15.475.41
2025-05-20VXRT1.81-15.475.41
2025-05-21VXRT1.81-15.475.41
2025-05-22VXRT1.81-15.475.41
2025-05-23VXRT1.81-15.475.41
2025-05-27VXRT1.67-23.525.43
2025-05-28VXRT1.67-23.526.46
2025-05-29VXRT1.67-23.526.46
2025-05-30VXRT1.67-23.526.46
2025-06-02VXRT1.67-23.526.46
2025-06-03VXRT1.67-23.526.46
2025-06-04VXRT1.67-23.526.46
2025-06-05VXRT1.67-23.526.46
2025-06-06VXRT1.67-23.526.46
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

1.67

Institutional Transactions

-23.52

Beta

1.15

Average Sales Estimate Current Quarter

2

Average Sales Estimate Next Quarter

2

Fair Value

Quality Score

24

Growth Score

39

Sentiment Score

2

Actual DrawDown %

98.4

Max Drawdown 5-Year %

-98.7

Target Price

4.67

P/E

Forward P/E

PEG

P/S

1.95

P/B

2.03

P/Free Cash Flow

EPS

-0.27

Average EPS Est. Cur. Y​

-0.29

EPS Next Y. (Est.)

-0.34

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-122.63

Relative Volume

0.43

Return on Equity vs Sector %

-151.5

Return on Equity vs Industry %

-133.5

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.05

EBIT Estimation

Vaxart, Inc. - Common Stock
Sector: Healthcare
Industry: Biotechnology
Employees: 105
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
stock quote shares VXRT – Vaxart, Inc. Stock Price stock today
news today VXRT – Vaxart, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VXRT – Vaxart, Inc. yahoo finance google finance
stock history VXRT – Vaxart, Inc. invest stock market
stock prices VXRT premarket after hours
ticker VXRT fair value insiders trading